Press releases

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer

In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…

Join our newsletter

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck